BACKGROUND: Anaplastic lymphoma kinase (ALK) gene rearrangements are detected in approximately 5% of cases of non-small cell lung cancer (NSCLC). Patients who are positive for ALK rearrangements may be successfully treated with the ALK inhibitor crizotinib. Because advanced-stage lung cancers are not suitable for surgical resection, approximately 70% of patients are diagnosed via preoperative specimens. In the current study, the authors evaluated the suitability of stained cytologic direct smears and cell blocks for fluorescence in situ hybridization (FISH) to determine ALK status compared with small biopsies. METHODS: A total of 493 consecutive patients with NSCLC were analyzed by FISH for ALK gene rearrangements. The analyzed sample...
BACKGROUND: Anaplastic lymphoma kinase (ALK) rearrangement represents a landmark in the targeted the...
Background and objective Besides epidermal growth factor receptor (EGFR) mutation, the non-small cel...
Patients with ALK gene rearrangements often manifest dramatic responses to crizotinib, an ALK inhibi...
Patients and methods Testing for Anaplastic Lymphoma Kinas (ALK) rearrangement is now recommended fo...
IntroductionThe standard diagnostic method for echinoderm microtubule-associated protein-like 4-anap...
Anaplastic lymphoma kinase (ALK) status analysis of lung cytological specimens should be successfull...
Background:The use of a standard immunohistochemistry (IHC) assay to detect the anaplastic lymphoma ...
Rearrangements of anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) define...
Introduction:Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non–small-cell lun...
International audienceIntroduction: Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7...
Fluorescence in situ hybridization (FISH) is currently used to detect non-small cell lung cancer (NS...
Objective: Predictive and prognostic markers have revolutionized personalized therapy in non-small c...
IntroductionBreak-apart fluorescence in situ hybridization (FISH) is the FDA-approved assay for dete...
International audienceAnaplastic lymphoma kinase (ALK) gene rearrangements in lung adenocarcinoma re...
Background: Lung cancer is a leading cause of deaths attributed to cancer worldwide. Epidermal growt...
BACKGROUND: Anaplastic lymphoma kinase (ALK) rearrangement represents a landmark in the targeted the...
Background and objective Besides epidermal growth factor receptor (EGFR) mutation, the non-small cel...
Patients with ALK gene rearrangements often manifest dramatic responses to crizotinib, an ALK inhibi...
Patients and methods Testing for Anaplastic Lymphoma Kinas (ALK) rearrangement is now recommended fo...
IntroductionThe standard diagnostic method for echinoderm microtubule-associated protein-like 4-anap...
Anaplastic lymphoma kinase (ALK) status analysis of lung cytological specimens should be successfull...
Background:The use of a standard immunohistochemistry (IHC) assay to detect the anaplastic lymphoma ...
Rearrangements of anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) define...
Introduction:Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non–small-cell lun...
International audienceIntroduction: Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7...
Fluorescence in situ hybridization (FISH) is currently used to detect non-small cell lung cancer (NS...
Objective: Predictive and prognostic markers have revolutionized personalized therapy in non-small c...
IntroductionBreak-apart fluorescence in situ hybridization (FISH) is the FDA-approved assay for dete...
International audienceAnaplastic lymphoma kinase (ALK) gene rearrangements in lung adenocarcinoma re...
Background: Lung cancer is a leading cause of deaths attributed to cancer worldwide. Epidermal growt...
BACKGROUND: Anaplastic lymphoma kinase (ALK) rearrangement represents a landmark in the targeted the...
Background and objective Besides epidermal growth factor receptor (EGFR) mutation, the non-small cel...
Patients with ALK gene rearrangements often manifest dramatic responses to crizotinib, an ALK inhibi...